Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo

Magdalena S Mroz, Niamh Keating, Joseph B Ward, Rafiquel Sarker, Silvie Amu, Gabriella Aviello, Mark Donowitz, Padraic G Fallon, Stephen J Keely

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

OBJECTIVE: Bile acids are important regulators of intestinal physiology, and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several intestinal disorders. Here, we investigated a role for FXR in regulating intestinal fluid and electrolyte transport and the potential for FXR agonists in treating diarrhoeal diseases.

DESIGN: Electrogenic ion transport was measured as changes in short-circuit current across voltage-clamped T84 cell monolayers or mouse tissues in Ussing chambers. NHE3 activity was measured as BCECF fluorescence in Caco-2 cells. Protein expression was measured by immunoblotting and cell surface biotinylation. Antidiarrhoeal efficacy of GW4064 was assessed using two in vivo mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation.

RESULTS: GW4064 (5 μmol/L; 24 h), a specific FXR agonist, induced nuclear translocation of the receptor in T84 cells and attenuated Cl(-) secretory responses to both Ca(2+) and cAMP-dependent agonists. GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells. In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca(2+) and cAMP-dependent secretory responses across ex vivo colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation in vivo. At the molecular level, FXR activation attenuated apical Cl(-) currents by inhibiting expression of cystic fibrosis transmembrane conductance regulator channels and inhibited basolateral Na(+)/K(+)-ATPase activity without altering expression of the protein.

CONCLUSIONS: These data reveal a novel antisecretory role for the FXR in colonic epithelial cells and suggest that FXR agonists have excellent potential for development as a new class of antidiarrheal drugs.

Original languageEnglish
Pages (from-to)808-817
Number of pages10
JournalGut
Volume63
Issue number5
Early online date7 Apr 2014
DOIs
Publication statusPublished - May 2014

Fingerprint

Diarrhea
Antidiarrheals
Caco-2 Cells
Cholera Toxin
Ovalbumin
Bile Acids and Salts
Biotinylation
Cystic Fibrosis Transmembrane Conductance Regulator
Ion Transport
Cytoplasmic and Nuclear Receptors
Immunoblotting
Electrolytes
Proteins
Fluorescence
Epithelial Cells
GW 4064
Therapeutics

Keywords

  • Animals
  • Antidiarrheals
  • Blotting, Western
  • Caco-2 Cells
  • Cells, Cultured
  • Colon
  • Diarrhea
  • Electrodiagnosis
  • Humans
  • Intestinal Mucosa
  • Ion Transport
  • Isoxazoles
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Cytoplasmic and Nuclear
  • Sodium-Hydrogen Antiporter
  • Evaluation Studies
  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this

Mroz, M. S., Keating, N., Ward, J. B., Sarker, R., Amu, S., Aviello, G., ... Keely, S. J. (2014). Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. Gut, 63(5), 808-817. https://doi.org/10.1136/gutjnl-2013-305088

Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. / Mroz, Magdalena S; Keating, Niamh; Ward, Joseph B; Sarker, Rafiquel; Amu, Silvie; Aviello, Gabriella; Donowitz, Mark; Fallon, Padraic G; Keely, Stephen J.

In: Gut, Vol. 63, No. 5, 05.2014, p. 808-817.

Research output: Contribution to journalArticle

Mroz, MS, Keating, N, Ward, JB, Sarker, R, Amu, S, Aviello, G, Donowitz, M, Fallon, PG & Keely, SJ 2014, 'Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo', Gut, vol. 63, no. 5, pp. 808-817. https://doi.org/10.1136/gutjnl-2013-305088
Mroz, Magdalena S ; Keating, Niamh ; Ward, Joseph B ; Sarker, Rafiquel ; Amu, Silvie ; Aviello, Gabriella ; Donowitz, Mark ; Fallon, Padraic G ; Keely, Stephen J. / Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo. In: Gut. 2014 ; Vol. 63, No. 5. pp. 808-817.
@article{bd9313e804a44b5085d7609d81b05233,
title = "Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo",
abstract = "OBJECTIVE: Bile acids are important regulators of intestinal physiology, and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several intestinal disorders. Here, we investigated a role for FXR in regulating intestinal fluid and electrolyte transport and the potential for FXR agonists in treating diarrhoeal diseases.DESIGN: Electrogenic ion transport was measured as changes in short-circuit current across voltage-clamped T84 cell monolayers or mouse tissues in Ussing chambers. NHE3 activity was measured as BCECF fluorescence in Caco-2 cells. Protein expression was measured by immunoblotting and cell surface biotinylation. Antidiarrhoeal efficacy of GW4064 was assessed using two in vivo mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation.RESULTS: GW4064 (5 μmol/L; 24 h), a specific FXR agonist, induced nuclear translocation of the receptor in T84 cells and attenuated Cl(-) secretory responses to both Ca(2+) and cAMP-dependent agonists. GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells. In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca(2+) and cAMP-dependent secretory responses across ex vivo colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation in vivo. At the molecular level, FXR activation attenuated apical Cl(-) currents by inhibiting expression of cystic fibrosis transmembrane conductance regulator channels and inhibited basolateral Na(+)/K(+)-ATPase activity without altering expression of the protein.CONCLUSIONS: These data reveal a novel antisecretory role for the FXR in colonic epithelial cells and suggest that FXR agonists have excellent potential for development as a new class of antidiarrheal drugs.",
keywords = "Animals, Antidiarrheals, Blotting, Western, Caco-2 Cells, Cells, Cultured, Colon, Diarrhea, Electrodiagnosis, Humans, Intestinal Mucosa, Ion Transport, Isoxazoles, Male, Mice, Mice, Inbred C57BL, Receptors, Cytoplasmic and Nuclear, Sodium-Hydrogen Antiporter, Evaluation Studies, Journal Article, Research Support, Non-U.S. Gov't",
author = "Mroz, {Magdalena S} and Niamh Keating and Ward, {Joseph B} and Rafiquel Sarker and Silvie Amu and Gabriella Aviello and Mark Donowitz and Fallon, {Padraic G} and Keely, {Stephen J}",
year = "2014",
month = "5",
doi = "10.1136/gutjnl-2013-305088",
language = "English",
volume = "63",
pages = "808--817",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "5",

}

TY - JOUR

T1 - Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo

AU - Mroz, Magdalena S

AU - Keating, Niamh

AU - Ward, Joseph B

AU - Sarker, Rafiquel

AU - Amu, Silvie

AU - Aviello, Gabriella

AU - Donowitz, Mark

AU - Fallon, Padraic G

AU - Keely, Stephen J

PY - 2014/5

Y1 - 2014/5

N2 - OBJECTIVE: Bile acids are important regulators of intestinal physiology, and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several intestinal disorders. Here, we investigated a role for FXR in regulating intestinal fluid and electrolyte transport and the potential for FXR agonists in treating diarrhoeal diseases.DESIGN: Electrogenic ion transport was measured as changes in short-circuit current across voltage-clamped T84 cell monolayers or mouse tissues in Ussing chambers. NHE3 activity was measured as BCECF fluorescence in Caco-2 cells. Protein expression was measured by immunoblotting and cell surface biotinylation. Antidiarrhoeal efficacy of GW4064 was assessed using two in vivo mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation.RESULTS: GW4064 (5 μmol/L; 24 h), a specific FXR agonist, induced nuclear translocation of the receptor in T84 cells and attenuated Cl(-) secretory responses to both Ca(2+) and cAMP-dependent agonists. GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells. In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca(2+) and cAMP-dependent secretory responses across ex vivo colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation in vivo. At the molecular level, FXR activation attenuated apical Cl(-) currents by inhibiting expression of cystic fibrosis transmembrane conductance regulator channels and inhibited basolateral Na(+)/K(+)-ATPase activity without altering expression of the protein.CONCLUSIONS: These data reveal a novel antisecretory role for the FXR in colonic epithelial cells and suggest that FXR agonists have excellent potential for development as a new class of antidiarrheal drugs.

AB - OBJECTIVE: Bile acids are important regulators of intestinal physiology, and the nuclear bile acid receptor, farnesoid X receptor (FXR), is emerging as a promising therapeutic target for several intestinal disorders. Here, we investigated a role for FXR in regulating intestinal fluid and electrolyte transport and the potential for FXR agonists in treating diarrhoeal diseases.DESIGN: Electrogenic ion transport was measured as changes in short-circuit current across voltage-clamped T84 cell monolayers or mouse tissues in Ussing chambers. NHE3 activity was measured as BCECF fluorescence in Caco-2 cells. Protein expression was measured by immunoblotting and cell surface biotinylation. Antidiarrhoeal efficacy of GW4064 was assessed using two in vivo mouse models: the ovalbumin-induced diarrhoea model and cholera toxin (CTX)-induced intestinal fluid accumulation.RESULTS: GW4064 (5 μmol/L; 24 h), a specific FXR agonist, induced nuclear translocation of the receptor in T84 cells and attenuated Cl(-) secretory responses to both Ca(2+) and cAMP-dependent agonists. GW4064 also prevented agonist-induced inhibition of NHE3 in Caco-2 cells. In mice, intraperitoneal administration of GW4064 (50 mg/mL) also inhibited Ca(2+) and cAMP-dependent secretory responses across ex vivo colonic tissues and prevented ovalbumin-induced diarrhoea and CTX-induced intestinal fluid accumulation in vivo. At the molecular level, FXR activation attenuated apical Cl(-) currents by inhibiting expression of cystic fibrosis transmembrane conductance regulator channels and inhibited basolateral Na(+)/K(+)-ATPase activity without altering expression of the protein.CONCLUSIONS: These data reveal a novel antisecretory role for the FXR in colonic epithelial cells and suggest that FXR agonists have excellent potential for development as a new class of antidiarrheal drugs.

KW - Animals

KW - Antidiarrheals

KW - Blotting, Western

KW - Caco-2 Cells

KW - Cells, Cultured

KW - Colon

KW - Diarrhea

KW - Electrodiagnosis

KW - Humans

KW - Intestinal Mucosa

KW - Ion Transport

KW - Isoxazoles

KW - Male

KW - Mice

KW - Mice, Inbred C57BL

KW - Receptors, Cytoplasmic and Nuclear

KW - Sodium-Hydrogen Antiporter

KW - Evaluation Studies

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1136/gutjnl-2013-305088

DO - 10.1136/gutjnl-2013-305088

M3 - Article

VL - 63

SP - 808

EP - 817

JO - Gut

JF - Gut

SN - 0017-5749

IS - 5

ER -